Why QTTB was halted on Sep 30 2026: phase 2 clinical data
QTTB-4.9%on Wed Sep 30 2026
Q32 Bio Inc. Common Stock was down 4.9% on the day at $9.06, ranked #226 on 41.9× its usual five-minute volume, when TapeRank recorded this trading halt at 09:31 ET during regular hours when it was halted. TapeRank recorded 3 events for QTTB that day, between 05:46 and 09:31 ET, and each is in the timeline below.
THE DAY ON THE LIST · 3 EVENTS
- 05:46 ETUNEXPLAINED MOVE · PRE-MARKET
$10.96 · ▲ 15.0% ON THE DAY · 46.1× 5M RVOL · RANK #2
No verdict was committed for this event.
THE ROW AND SESSION LEVELS AT 05:46 ET
LAST10.96DAY▲ 15.0%5 MIN▲ 2.72%5M RVOL46.1×5M $VOL$71KFLOAT*29.8MRANK#2SESSIONPRE-MARKETVWAP10.95HOD10.76LOD10.12OR HIGH—OR LOW—PREV CLOSE9.53PM HIGH10.76PM LOW10.12GAP▲ 12.49% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 09:24 ETMOVER · PRE-MARKET
$11.46 · ▲ 20.2% ON THE DAY · 431× 5M RVOL · RANK #1
JUSTIFIEDCONFIDENCE4/5Q32 Bio is up 15.3%, with an acceleration to 8.81% in five minutes, after reporting additional 36-week and off-drug durability results from its SIGNAL-AA Phase 2a trial. The clinical update describes meaningful efficacy and durable responses in severe alopecia areata, a concrete biotech catalyst that supports a sharp pre-market repricing.
WHYA 15.3% move on positive Phase 2 durability data in a 33-patient trial is substantial but proportionate to potentially differentiated clinical evidence.ANALYZED 09:23 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:24 ET
LAST11.46DAY▲ 20.2%5 MIN▲ 12.24%5M RVOL431×5M $VOL$1.6MFLOAT*29.8MRANK#1SESSIONPRE-MARKETVWAP10.71HOD11.18LOD9.79OR HIGH—OR LOW—PREV CLOSE9.53PM HIGH11.18PM LOW9.79GAP▲ 13.01% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 09:31 ETHALT · REGULAR
HALTED AT $9.06 · ▼ 4.9% ON THE DAY · 41.9× 5M RVOL · RANK #226
The same verdict as at 09:24 ET.
THE ROW AND SESSION LEVELS AT 09:31 ET
LAST9.06DAY▼ 4.9%5 MIN▼ 16.50%5M RVOL41.9×5M $VOL$1.8MFLOAT*29.8MRANK#226SESSIONREGULARVWAP10.63HOD11.68LOD9.06OR HIGH10.40OR LOW9.06PREV CLOSE9.53PM HIGH11.68PM LOW9.79GAP▲ 9.13%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.
THE SESSION
- 09:30 ETOpened at $10.40, +9.1% on the previous close of $9.53
- 09:30 ETRegular-session high, $10.40
- 09:30 ETHalted (LUDP); resumed 09:35 ET, after 5 minutes
- 12:40 ETRegular-session low, $7.88
- 15:59 ETLast trade of the regular session, $8.27, -13.2% on the previous close of $9.53
- Volume: 4.4M shares in regular hours, 705K before the open
QTTB opened at $10.40 after rising as high as $11.46 premarket, as TapeRank tied the move to Q32 Bio’s additional 36-week and initial off-drug results from its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata. The stock halted at 09:30 ET and resumed five minutes later, then fell to a session low of $7.88 before ending regular trading at $8.27, below the previous close of $9.53.
WRITTEN THU OCT 15 2026 17:59 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:19 ETQ32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of ResponseBenzinga
- 05:20 ET8-K — Regulation FD Disclosure; Other Events; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list